Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000996521 | SCV001151262 | uncertain significance | not provided | 2019-04-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002067618 | SCV002444297 | likely benign | Neurofibromatosis, type 1 | 2024-01-25 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001727835 | SCV005205176 | likely benign | not specified | 2024-06-17 | criteria provided, single submitter | clinical testing | Variant summary: NF1 c.4269+22_4269+25delGCTA is located at a position not widely known to affect splicing. Consensus agreement among computation tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.00014 in 249196 control chromosomes, predominantly at a frequency of 0.00025 within the African or African-American subpopulation in the gnomAD database. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.4269+22_4269+25delGCTA in individuals affected with Neurofibromatosis Type 1 and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 808252). Based on the evidence outlined above, the variant was classified as likely benign. |
Diagnostic Laboratory, |
RCV000996521 | SCV001743298 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV001727835 | SCV001972317 | benign | not specified | no assertion criteria provided | clinical testing |